Multicenter Study Evaluating New Surgery and Care Approaches for Lung Cancer in Patients 65 and Older Including Perioperative Treatment and Rehabilitation

What this Trial Is About

Researchers are studying elderly patients aged 65 and older with non-small cell lung cancer to develop an optimized treatment model that covers the entire care process. This includes creating a clinical database, risk stratification and early-warning systems for surgery, personalized surgical strategies, integrated perioperative treatments combining traditional Chinese and Western medicine, and tailored postoperative rehabilitation. The goal is to improve surgical safety, long-term outcomes, and overall management for elderly lung cancer patients through a multicenter prospective clinical trial. Participants will be randomly assigned to one of three surgical treatment groups standard lobectomy, segmentectomy, or wedge resection, all combined with mediastinal lymph node sampling. Treatment approaches are guided by preoperative geriatric risk scores and tumor characteristics. Postoperative management includes adaptive perioperative therapies based on minimal residual disease monitoring and biomarker results, with low-risk patients receiving less intensive care and high-risk patients receiving more comprehensive therapy. The study also involves multidisciplinary teams to provide personalized rehabilitation and integrated traditional Chinese medicine interventions throughout the perioperative period. During the study, participants will undergo comprehensive assessments including geriatric evaluations, imaging, pathology, and biomarker analysis before and after surgery. Researchers will monitor postoperative complications, overall survival for up to four years, and disease-free survival after recurrence. Follow-up includes regular visits and real-time remote monitoring to support rehabilitation and treatment adherence. Safety and long-term outcomes are closely tracked, with the entire study expected to continue through 2028.

Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients